Vigil Neuroscience Company Profile - aVenture Research
Vigil Neuroscience
Vigil Neuroscience was a clinical-stage biotech developing TREM2-activating microglia therapies for patients with rare and common neurodegenerative diseases.
Vigil Neuroscience was a clinical-stage, microglia-focused neuroscience drug-development company whose work rested on microglial biology—the sentinel immune cells of the brain that respond to disease-caused damage—as its organizing scientific thesis. It utilized modern neuroscience drug development tools across multiple therapeutic modalities to develop precision-based therapies.
Its precision-medicine approach began with rare, genetically defined diseases and then expanded into larger, more common neurodegenerative diseases. Its candidates were designed as TREM2 agonists, activating a microglial receptor whose dysfunction is linked to neurodegeneration as the therapeutic mechanism.